

Vanadium species	Cell signalling Pathways	Therapeutic properties	References
Vanadyl Sulfate	ras-ERK	Antidiabetic	1
Vanadate	P42 and p44 mapk	Antidiabetic	2,3
Bis(acetylacetonato)-Oxovanadium(IV), Bis(maltolato)-Oxovanadium(IV) and Sodium Metavanadate	AKT	antilipolytic	4
Bis(1-oxy-2-pyridinethiolato) oxovanadium (IV)	AKT	Cardioprotective	5, 6
Vanadium(IV) oxo-bis(maltolato)	AKT	Antidiabetic	7, 8

1. D. Sanna, V. Ugone, G. Lubinu, G. Micera and E. Garribba, *J. Inorg. Biochem.*, 2014, **140**, 173–184.
2. D. Sanna, G. Micera and E. Garribba, *Inorg. Chem.*, 2010, **49**, 174–87.
3. S. K. Pandey, J. F. Théberge, M. Bernier and A. K. Srivastava, *Biochemistry*, 1999, **38**, 14667–75.
4. F. D’Onofrio, M. Q. Le, J. L. Chiasson and A. K. Srivastava, *FEBS Lett.*, 1994, **340**, 269–75.
5. Y. Shechter, J. Li, J. Meyerovitch, D. Gefel, R. Bruck, G. Elberg, D. S. Miller and A. Shisheva, *Mol. Cell. Biochem.*, **153**, 39–47.
6. J. K. Slack-Davis, K. H. Martin, R. W. Tilghman, M. Iwanicki, E. J. Ung, C. Autry, M. J. Luzzio, B. Cooper, J. C. Kath, W. G. Roberts and J. T. Parsons, *J. Biol. Chem.*, 2007, **282**, 14845–52.
7. N. A. Chatzizacharias, G. P. Kouraklis and S. E. Theocharis, *Histol. Histopathol.*, 2008, **23**, 629–50.
8. I. Tanjoni, C. Walsh, S. Uryu, A. Tomar, J.-O. Nam, A. Mielgo, S.-T. Lim, C. Liang, M. Koenig, C. Sun, N. Patel, C. Kwok, G. McMahon, D. G. Stupack and D. D. Schlaepfer, *Cancer Biol. Ther.*, 2010, **9**, 764–77.